Intervention group for Hypertension

Phase-Based Progress Estimates
University of Alberta, Edmonton, Canada
Hypertension+2 More
Diuretic algorithm - Other
All Sexes
What conditions do you have?

Study Summary

This study aims to reduce fluid overload in order to control blood pressure of hypertensive CKD patients using bio-impedance assessment of fluid status and using a diuretic therapy algorithm.

Eligible Conditions

  • Hypertension

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 12 months

12 months
Blood pressure
Fluid status
Vascular stiffness

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Control group
1 of 2
Intervention group
1 of 2
Active Control
Experimental Treatment

172 Total Participants · 2 Treatment Groups

Primary Treatment: Intervention group · No Placebo Group · N/A

Intervention group
Experimental Group · 1 Intervention: Diuretic algorithm · Intervention Types: Other
Control groupNoIntervention Group · 1 Intervention: Control group · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
Closest Location: University of Alberta · Edmonton, Canada
Photo of university of alberta hospital  1Photo of university of alberta hospital  2Photo of university of alberta hospital  3
2006First Recorded Clinical Trial
11 TrialsResearching Hypertension
298 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have uncontrolled hypertension.
You have an eGFR of 15-45 ml/min/1.73 m2.
You have a fluid overload of more than 5% of estimated normal ECFV, as assessed by Bio-impedance spectroscopy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.